On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study.

Cytochrome P450 2C9 (CYP2C9) plays a key role in the metabolism of clinical drugs. CYP2C9 is a genetically polymorphic enzyme and some of its allelic variants have less activity compared to the wild-type form. Drugs with a narrow therapeutic index may cause serious toxicity to the individuals who carry such allele. CYP2C9*13, firstly identified by some of the present authors in a Chinese poor metabolizer of lornoxicam, is characterized by mutation encoding Leu90Pro substitution. Kinetic experiments show that CYP2C9*13 has less catalytic activity in elimination of diclofenac and lornoxicam in vitro. In order to explore the structure-activity relationship of CYP2C9*13, the three-dimensional structure models of the substrate-free CYP2C9*1 and its variant CYP2C9*13 are constructed on the basis of the X-ray crystal structure of human CYP2C9*1 (PDB code 1R9O) by molecular dynamics simulations. The structure change caused by Leu90Pro replacement is revealed and used to explain the dramatic decrease of the enzymatic activity in clearance of the two CYP2C9 substrates: diclofenac and lornoxicam. The trans configuration of the bond between Pro90 and Asp89 in CYP2C9*13 is firstly identified. The backbone of residues 106-108 in CYP2C9*13 turns over and their side chains block the entrance for substrates accessing so that the entrance of *13 shrinks greatly than that in the wild-type, which is believed to be the dominant mechanism of the catalytic activity reduction. Consequent docking study which is consistent with the results of the kinetic experiments by Guo et al. identifies the most important residues for enzyme-substrate complexes.

[1]  C Masimirembwa,et al.  Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. , 2000, Biochemical and biophysical research communications.

[2]  D. Eisenberg,et al.  Assessment of protein models with three-dimensional profiles , 1992, Nature.

[3]  K Chiba,et al.  Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. , 1998, Biochemical pharmacology.

[4]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[5]  T. Kubota,et al.  Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele , 2000, European Journal of Clinical Pharmacology.

[6]  T. Leemann,et al.  Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. , 1993, Life sciences.

[7]  F. Guengerich,et al.  Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. , 2001, Chemical research in toxicology.

[8]  D. Mansuy,et al.  Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. , 2003, Archives of biochemistry and biophysics.

[9]  P. Bonnabry,et al.  Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam , 2004, European Journal of Clinical Pharmacology.

[10]  R. Wade,et al.  Comparison of the dynamics of substrate access channels in three cytochrome P450s reveals different opening mechanisms and a novel functional role for a buried arginine , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Ilme Schlichting,et al.  Structure and chemistry of cytochrome P450. , 2005, Chemical reviews.

[12]  D. Zhong,et al.  Identification of a novel variant CYP2C9 allele in Chinese. , 2004, Pharmacogenetics.

[13]  U. Schwarz,et al.  Clinical relevance of genetic polymorphisms in the human CYP2C9 gene , 2003, European journal of clinical investigation.

[14]  G. Loew,et al.  Homology modeling and substrate binding study of human CYP2C9 enzyme , 1999, Proteins.

[15]  D W Nebert,et al.  P450 genes: structure, evolution, and regulation. , 1987, Annual review of biochemistry.

[16]  Barry C Jones,et al.  Development of a combined protein and pharmacophore model for cytochrome P450 2C9. , 2002, Journal of medicinal chemistry.

[17]  H. Zhou,et al.  Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13 , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  Sason Shaik,et al.  Theoretical perspective on the structure and mechanism of cytochrome P450 enzymes. , 2005, Chemical reviews.

[19]  Stewart B Kirton,et al.  In silico methods for predicting ligand binding determinants of cytochromes P450. , 2004, Current topics in medicinal chemistry.

[20]  Yifan Zhang,et al.  ROLE OF CYP2C9 AND ITS VARIANTS (CYP2C9*3 AND CYP2C9*13) IN THE METABOLISM OF LORNOXICAM IN HUMANS , 2005, Drug Metabolism and Disposition.

[21]  T. Andersson,et al.  Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. , 2001, Journal of medicinal chemistry.

[22]  S. Sligar,et al.  Electrostatic control of the substrate access channel in cytochrome P-450cam. , 1994, Biochemistry.

[23]  Toshimasa Tanaka,et al.  Characterization of the CYP3A4 active site by homology modeling. , 2004, Chemical & pharmaceutical bulletin.

[24]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.

[25]  J. Goldstein,et al.  Biochemistry and molecular biology of the human CYP2C subfamily. , 1994, Pharmacogenetics.

[26]  Kaoru Kobayashi,et al.  CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.

[27]  M. Sutcliffe,et al.  Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity. , 2003, The Biochemical journal.

[28]  Eric F. Johnson,et al.  The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.

[29]  C David Stout,et al.  Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution: evidence for an induced fit model of substrate binding. , 2003, Biochemistry.

[30]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[31]  C. Jang,et al.  Allele and genotype frequencies of CYP2C9 in a Korean population. , 2005, British journal of clinical pharmacology.

[32]  Xiaoyan Chen,et al.  Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. , 2005, British journal of clinical pharmacology.

[33]  Erik Eliasson,et al.  The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro , 2001, European Journal of Clinical Pharmacology.